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BACKGROUND: The development of a successful immunotherapy is hampered by an ineffective T-cell repertoire against tumour
antigens and the inability of the patient’s immune system to overcome tolerance-inducing mechanisms. Here, we test the specific
recognition and lytical potential of allo-restricted CD8
þ T cells against Ewing tumour (ET) associated antigens Enhancer of Zeste,
Drosophila Homolog 2 (EZH2), and Chondromodulin-I (CHM1) identified through previous microarray analysis.
METHODS: Following repetitive CHM1
319 (VIMPCSWWV) and EZH2
666 (YMCSFLFNL) peptide-driven stimulations with
HLA-A*0201
þ dendritic cells (DC), allo-restricted HLA-A*0201
  CD8
þ T cells were stained with HLA-A*0201/peptide
multimers, sorted and expanded by limiting dilution.
RESULTS: Expanded T cells specifically recognised peptide-pulsed target cells or antigen-transfected cells in the context of
HLA-A*0201 and killed HLA-A*0201
þ ET lines expressing the antigen while HLA-A*0201
– ET lines were not affected. Furthermore,
adoptively transferred T cells caused significant ET growth delay in Rag2
 / gC
 /  mice. Within this context, we identified the
CHM1
319 peptide as a new candidate target antigen for ET immunotherapy.
CONCLUSION: These results clearly identify the ET-derived antigens, EZH2
666 and CHM1
319, as suitable targets for protective
allo-restricted human CD8
þ T-cell responses against non-immunogenic ET and may benefit new therapeutic strategies in ET patients
treated with allogeneic stem cell transplantation.
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T-cell based tumour immunology suffers from a principal
dilemma: tumour-derived peptides are frequently self-antigens
associated with MHC class I molecules. Moreover, T cells with
high affinity for such antigens undergo negative selection and
peripheral tolerance mechanisms diminish their number
or eliminate self-peptide specific cytotoxic T cells. Nevertheless,
as the T-cell repertoire has not been educated to ignore self
antigens presented by foreign MHC molecules, allo-restricted
T cells may represent a comprehensive repository for tumour-
specific T cells (Felix and Allen, 2007).
Allogeneic stem cell transplantation (SCT) is an established
treatment for leukaemia where donor T cells induce a graft-vs-
leukaemia response that can eradicate residual malignant cells
(Kolb et al, 1995), and is now being explored as a treatment for a
variety of other haematologic and non-haematologic malignancies
(Childs et al, 2000). For malignant peripheral neuroectodermal
tumours (Ewing tumour, ET), patients with vast bone affection
and poor prognosis, allogeneic SCT represents a therapy option
(Burdach et al, 2000, 2009). Koscielniak et al (2005) and Lucas et al
(2008) reported tumour regression in ET patients with advanced
disease immediately after allogeneic SCT. This possible graft-vs-ET
effect, however, may be associated with a pronounced toxicity
potential of a graft-vs-host response in this therapeutic approach.
During the past years, methods emerged to identify, isolate, and
expand tumour peptide-specific allo-restricted T cells ex vivo
(Moris et al, 2001; Dutoit et al, 2002; Mutis et al, 2002; Amrolia
et al, 2003; Whitelegg et al, 2005; Schuster et al, 2007), anticipating
their potential use for adoptive immunotherapy (Rosenberg et al,
2008) for example, to replace common donor lymphocyte infusion
(DLI) with tumour-specific allo-restricted T cells. We describe
here, an HLA-A*0201-multimer approach using peptides derived
from genes identified to be overexpressed in ET by microarray
analysis (Staege et al, 2004). These peptide/MHC multimers
enabled the selection of allo-restricted tumour-antigen specific
T cells from an allo-reactive T-cell pool. Such T cells were peptide-
specific and cytotoxic against ET cells with the appropriate
HLA-expression and significantly delayed tumour growth after
adoptive transfer in a xenograft mouse model.
MATERIALS AND METHODS
Cell lines
MHHES1, SK-ES1, SK-N-MC, TC71 (ET cell lines), CHP126,
MHHNB11, SH-SY5Y, SIMA (neuroblastoma cells), and NALM6,
697, cALL2 (paediatric human B-cell precursor leukaemic lines)
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swere obtained from the German Collection of Microorganisms
and Cell Cultures (DSMZ; Braunschweig, Germany). The HLA-
A*0201
þ melanoma cell line SK-MEL29 was provided by L Old
(Memorial Sloan-Kettering Cancer Institute, New York, NY, USA).
A673 (ET cells) and Cos-7 (Simian SV40-transformed fibroblasts)
were obtained from ATCC (LGC Standards GmbH, Wesel,
Germany), the TAP-defective HLA*A0201
þ T2 cell line (LCL
somatic cell hybrid) was from P Cresswell (Yale University School
of Medicine, New Haven, CT, USA). The HLA-A*0201
– erythroid
leukaemia cell line K562 was a gift from A Knuth and E Ja ¨ger
(Krankenhaus Nordwest, Frankfurt, Germany). HLA-A*0201
–
SBSR-AKS ET cells were described previously (Richter et al,
2009). All cell lines are routinely tested for purity (e.g.,
translocation product, surface antigen or HLA-phenotype) and
mycoplasma contamination. Lymphoblastoid cell lines (LCL) were
generated by EBV transformation of peripheral blood B cells from
HLA-A*0201
þ healthy donors by use of a mini-EBV plasmid
(Moosmann et al, 2002). The supernatant was provided by Josef
Mautner and Andreas Moosmann, Helmholtz-Zentrum Mu ¨nchen.
Tumour cell lines including K562 cells were cultured in RPMI
1640 or DMEM (only Cos-7 and SK-Mel29; Life Technologies,
Paisley, Scotland) supplemented with 10% foetal calf serum (FCS,
Biochrom, Berlin, Germany), 100Uml
 1 penicillin, 100mgml
 1
streptomycin, and 2mM glutamine (all from Life Technologies).
RPMI 1640 medium for LCL and T2 cells was supplemented with
10% human AB serum, 2mM L-glutamine, 1mM Na-pyruvate, non-
essential amino acids, and 50mgml
 1 gentamycine (all from Life
Technologies).
Isolation of PBMC
Peripheral blood mononuclear cells (PBMCs) were isolated from
human peripheral blood samples of healthy donors (obtained with
IRB approval and informed consent from the DRK-Blutspende-
dienst Baden-Wu ¨rttemberg-Hessen in Ulm, Germany) by centri-
fugation over Ficoll-Paque (GE Healthcare, Freiburg, Germany)
according to the supplier’s recommendations.
Generation of dendritic cells (DCs)
CD14
þ cells were isolated from PBMCs with anti-human CD14
magnetic particles (BD Biosciences, Heidelberg, Germany) accord-
ing to the manufacturer’s instructions. Purity of cells was
confirmed by flow cytometry on a FACS Calibur (BD Biosciences).
CD14
þ monocytes were cultured in X-Vivo15 (Biowhittaker/
Cambrex Bio Science Verviers, Apen, Germany)/1% AB serum
(Biowhittaker/Cambrex) with 1000IUml
 1 IL-4 (R&D Systems,
Wiesbaden, Germany) and 800IUml
 1 GM-CSF (Leukine sargra-
mostim, Bayer Health Care, Leverkusen, Germany) at a concentra-
tion of 3 10
5ml
 1 with 25–30ml per 75cm
2 cell culture flask
(TPP, Trasadingen, Switzerland) at 371C and 5% CO2. On day 3,
cytokines were replaced. On day 6 of culture, DC maturation was
induced by adding a cytokine cocktail consisting of 10ngml
 1
TNFa,1 0 n g m l
 1 IL-1b, 1000IUml
 1 IL-6 (R&D Systems), and
1mgml
 1 PGE2 (Cayman Europe, Tallin, Estonia). On culture day 8
and 9, cells displayed a mature phenotype as evidenced by flow
cytometry. DCs were considered mature when positive for CD86,
CD83, and HLA-DR.
Isolation of CD8
þ T cells
Untouched CD8
þ T cells were purified from human HLA-A*0201
–
PBMCs by negative isolation technique using a cocktail of biotin-
conjugated non-CD8 monoclonal antibodies and anti-biotin micro
beads followed by depletion of magnetically labelled cells on LS
columns (all from Miltenyi Biotec, Bergisch Gladbach, Germany).
Purity of isolated CD8
þ T cells was confirmed by flow cytometry.
In vitro priming
Mature DCs were resuspended in T-cell medium (AIM-V
supplemented with 5% human AB serum, 2mM L-glutamine,
and 50mgml
 1 gentamycine) and pulsed with selected peptides at
a concentration of 30–50mM in the presence of 20mgml
 1 b2M
(Sigma, Taufkirchen, Germany) for 4h at 371C and 5% CO2
washed and were then irradiated at 35Gy, and used for T-cell
priming immediately or stored in liquid nitrogen for subsequent
experiments. CD8
þ T cells from an HLA-A*0201
  donor were
stimulated with allogeneic HLA-A*0201
þ DCs in 200ml of T-cell
medium in a stimulator to responder rate of 1:20 (5 10
3 DCs per
well:10
5 CD8
þ T cells per well). For priming, T cells and DCs were
co-cultured with 10ngml
 1 rhIL-12 and 1000Uml
 1 rhIL-6 and
after 1 week were restimulated with the same number of loaded
DCs in the presence of 5ngml
 1 rhIL-7 and 100Uml
 1 rhIL-2.
Multimer-staining and cell sorting
Two weeks after the beginning of in vitro priming all activated
T cells were pooled and stained with a specific peptide/
HLA-A*0201-Pentamer-PE (Proimmune, Oxford, UK) and coun-
terstained with an anti-human CD8-FITC mAb (BD Biosciences)
for cell sorting. Isotype IgG mAb and irrelevant peptide/
HLA-A*0201-Pentamer-PE served as a control. Cell sorting was
executed on a FACS Aria (BD Biosciences).
V b analysis of T-cell receptor repertoire
To determine the status of clonality of T-cell clones, the IOTest
Beta Mark Kit (Beckman Coulter, Brea, CA, USA) was used. This
kit is designed for flow cytometric determination of the T-cell
receptor (TCR) Vb repertoire of human T lymphocytes and allows
testing for 24 different Vb specificities that cover about 70% of the
normal human TCR Vb repertoire.
Limiting dilution
After purifying peptide-specific T cells through peptide/
HLA-A*0201-multimer-mediated cell sorting, isolated T cells were
expanded using limiting dilution. Expansion was conducted in
round-bottom 96-well plates in 200ml T-cell medium supplemen-
ted with anti-CD3 (30ngml
 1), rhIL-2 (50IUml
 1), rhIL-15
(2ngml
 1), irradiated LCL; 1 10
5 per well and irradiated PBMCs
pooled from three different healthy donors (5 10
4 per well) as
feeder cells as previously described (Parker et al, 1994). Cytokines
and 100ml medium/well were replaced after 1 week. Expanded
T cells were further characterized in ELISpot assays.
ELISpot-assay
The 96-well mixed cellulose ester plates (MultiScreen-HA Filter
Plate, 0.45mm, Millipore, Eschborn, Germany) were coated over-
night at 41C with 50ml per well of capture antibody solution
(all Mabtech, Hamburg, Germany, Supplementary Table SII) in
PBS. Plates were then washed four times with PBS and
subsequently blocked with 150ml per well of TCM for 1h at
371C. When peptide-loaded T2 cells were used, they were pre-
incubated with 30–50mM peptide for at least 2h at 371C. When ET
cells were used, they were pre-incubated with 100Uml
 1 IFN-g
48h before use in the assay. After blocking, the T cells to be
investigated were either adjusted at a concentration of 2 10
6
cellsml
 1 in TCM and 50ml of serial dilutions (Granzyme B) or
50ml containing 1000 T cells (IFN-g) were plated into the wells and
incubated for 30min at 371C. The target cells were washed,
resuspended in TCM and 50ml per well allocated per well
containing 20000 cells. For HLA-A*0201 blocking of A673, the
HLA class I (W6/32) specific antibody (Abcam, Cambridge, UK)
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swas added to the wells at a concentration of 10mgml
 1. Peripheral
blood mononuclear cells (PBMCs) isolated from an HLA-A*0201
þ
healthy donor were either stimulated with 3mgml
 1 OKT3 for 48h
or left untreated. Before application to the assay, cells were
irradiated with 30Gy and washed thrice with PBS. The plates
were then incubated for 20h at 371C. Subsequently, the plates were
washed six times with PBS/0.05% Tween 20 (Sigma). Then wells
were incubated for 2h at 371C with 200ml of biotinylated
secondary antibody (all Mabtech, Supplementary Table S2)
diluted in PBS/0.5% BSA. The plates were washed six times with
PBS/0.05% Tween 20. A volume of 200ml per well of Streptavidin-
HRP (Mabtech) diluted 1/1000 was added and plates were
incubated for 1h at RT. After three washes with PBS/0.05% Tween
20 followed by three final washes with PBS, 100ml of 3-Amino-9-
ethyl-carbazole solution (Sigma) was added and incubated for
4–8min. Colour-development was stopped by washing under
running tap water. Spots in dried plates were counted on an AID-
ELIRIFL04 ELISpot reader (Autoimmun Diagnostika, Strassberg,
Germany).
Tumour challenge and adoptive T-cell transfer in
Rag2
 / cC
 / mice
Immunodeficient Rag2
 / gC
 /  mice on a BALB/c background
were obtained from the Central Institute for Experimental Animals
(Kawasaki, Japan). Mice were bred and maintained in our animal
facility under pathogen-free conditions in accordance with the
institutional guidelines and approval by local authorities. Each
mouse was challenged by s.c. intra-inguinal injection of 2 10
6
A673 ET cells and monitored for tumour growth. Three days after
tumour challenge, each mouse received either 2 10
6 EZH2-15
(n¼7) or 2 10
6 CHM1-6 (n¼6) T cells intravenously or were left
untreated (control group, n¼8). At 17 days after tumour
challenge, mice were killed and analysed for tumour weight.
RESULTS
Histone methyltransferase EZH2 and chondromodulin-I
are strongly upregulated in Ewing tumours
The EWS-FLI1 fusion protein, which is pathognomonic in 85%
of ET, represents an ideal immunological target in search of
immunogenic peptides for T-cell based therapy. However, we were
not able to validate any peptide from this fusion region as a good
binder to, for example, HLA-A*0201 (Meyer-Wentrup et al, 2005).
Therefore, we reinforced our endeavours to identify cytotoxic
T-cell epitopes of other antigens that are specifically expressed in
ET. In a previous microarray analysis, we recognised the histone
(lysine) methyl-transferase Enhancer of Zeste, Drosophila,
Homolog 2 (EZH2) and Chondromodulin-I (CHM1) as strongly
upregulated genes in ET (Staege et al, 2004) and demonstrated that
EZH2 has a critical role in ET pathology by determining the
oncogenicity and stem cell phenotype of this tumour (Richter et al,
2009). As shown in Figure 1A, CHM1 expression was not observed
in any normal tissue analyzed, whereas EZH2 is expressed
ubiquitously at low levels, with elevated levels in bone marrow,
rectum, testis, and thymus. In addition, real-time RT–PCR
demonstrated that other childhood malignancies including com-
mon acute lymphoblastic leukaemia (cALL) and neuroblastoma
showed a significantly lower or no expression of CHM1 and EZH2,
respectively (Figure 1B).
Selection of HLA-A*0201-restricted peptides derived
from ET antigens
HLA-A*0201 epitope binding analyses and presumed proteasomal
cleavage prediction were performed by use of SYFPEITHI
(Rammensee et al, 1999), BIMAS (Parker et al, 1994), and NetCTL
(Larsen et al, 2005) algorithms (see Supplementary Information).
Selected peptides and their scores are shown in Supplementary
Table SI. Synthesised peptides were validated for binding to HLA-
A*0201 onto T2 cells. Peptide dependent increase of HLA-A*0201
expression measured by flow cytometry is shown (Supplementary
Figure 1). Specific binding was correlated to influenza matrix
peptide (GILGFVFTL) binding. Peptide CHM1
319 and previously
published peptide EZH2
666 (Steele et al, 2006) demonstrated strong
HLA-A*0201 binding whereas peptide CHM1
38 revealed no
binding at all in this assay. Peptides CHM1
319 and EZH2
666 were
chosen for subsequent in vitro priming of T cells.
Selection of peptide- and ET-specific T cells
Although autologous HLA-A*0201 restricted CD8
þ T cells
specific for either EZH2
666 or CHM1
319 peptide were easily
identified, they were in no case able to recognise HLA-A*0201
þ
ET cells (Supplementary Figure 2). Therefore, we focused our
attention on the establishment of peptide-specific allo-restricted T
cells. For this purpose, in vitro generated, mature HLA-A*0201
þ
DC were pulsed with either CHM1
319 or EZH2
666, which were then
used to stimulate purified HLA-A*0201
  CD8
þ T cells twice in a
7-day interval (see Materials and Methods). Subsequently,
to separate allo-reactive CTL from allo-restricted CTL, peptide/
HLA-A*0201
þ multimers were used to label allo-restricted CD8
þ
T cells (Borg et al, 2005). The CTL peptide/HLA-A*0201
þ
multimer staining was highly specific and usually stained
only between 0.1–0.4% cells of the stimulated T-cell population.
Peptide-multimer-positive T cells were sorted by FACS. Figure 2A
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Figure 1 Antigen-specific expression profile (gray). (A) Expression
profile of EZH2 and CHM1 in Ewing tumours (ET, red) in comparison to
normal (black), and foetal tissue (FT, gray). Ewing tumour, FT and normal
tissue samples were analyzed using EOS-Hu01 microarrays (Staege et al,
2004). (B) Expression of EZH2 and CHM1 was evaluated by real-time
RT–PCR in different paediatric tumour cell lines. Error bars represent s.d.
of triplicate experiments. Abbreviation: NTC¼non-template control.
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sprovides an example of these marginal T-cell populations that were
positive for both peptide/HLA-A*0201-multimer and CD8, here
specifically stained with the CHM1
319/multimer. Subsequently,
sorted T cells were expanded using limiting dilution and tested for
specificity in ELISpot assays.
In a first screen, the expanded T-cell lines were tested for
specific IFN-g release against individual peptides: T2 cells were
either pulsed with CHM1
319 or EZH2
666, or the influenza-derived
peptide (GILGFVFTL) as a control. For example, of the T cells
initially specifically selected with the CHM1
319/HLA-A*0201-
multimer, 96 cell g release against CHM1 lines were grown and
tested for specific IFN-
319 peptide. The results of seven lines are
shown in Figure 2B, left. One line that passed this screen (CHM1-6)
was further expanded and retested on T2 cells (Supplementary
Figure 3, left) as well as Cos-7 cells, which were double-transfected
with an HLA-A*0201 expression plasmid and a CHM1 cDNA
encoding vector, confirming specific recognition and peptide
presentation (P¼0.01, two-tailed t-test; Figure 2C, left). Further-
more, subsequent analysis demonstrated correct HLA-A*0201-
restricted recognition of ET cell lines (P¼0.007, two-tailed t-test;
Figure 2C, right). A similar screen for T cells specific for EZH2
666
peptide identified three lines EZH2-11, -15, and -24 with peptide-
specific recognition on T2 cells (Figure 2B, right). One line that
was further expanded and repeatedly tested (Supplementary Figure
3, right), revealed specific recognition of processed EZH2
666
peptide on double-transfected Cos-7 cells (P¼0.008, two-tailed
t-test; Figure 2C, left) and HLA-A*0201 specific identification
of ET lines (P¼0.002, two-tailed t-test; Figure 2C, right). In flow
cytometry, these two lines CHM1-6 (specific for CHM1
319) and
EZH2-15 (specific for EZH2
666) were only positive for Vb 13.2
(CHM1-6) or Vb 13.1 (EZH2-15) (data not shown). Both lines
stained positive with their respective peptide/HLA-A*0201-multi-
mer (Figure 2D) and were CD27
low, CD28
–, CD45RA
low, CD56
þ,
CD62L
–, IL7R
–, CCR5
–, and CCR7
– (data not shown).
Allo-restricted T cells mediate Ewing tumour-specific
cytotoxicity
To test for ET specific cell-mediated cytotoxicity of allo-restricted
T-cell lines, we investigated their ability for antigen-specific
granzyme B release in the ELISpot assay (Shafer-Weaver et al,
2003; Anderson et al, 2007). Both T-cell lines demonstrated a
specific granzyme B release only when tested in the appro-
priate antigen/HLA-A*0201-restriction combination, while
HLA-A*0201
– ET cells recognition (SBSR-AKS cells) and possible
NK-cell activity, as tested on K562 cells, was not higher than
background level of pure T cells (overall Po0.05 until effector to
target ratio reached 1.25, Welch two sample t-test; Figures 3A
and B). Retesting at a fixed effector to target ratio of 10:1 only
identified a significant granzyme B release when these T-cell lines
recognised HLA-A*0201
þ ET cells (all Po0.05; two-tailed t-test;
Figure 3C). HLA-restricted recognition was reversed after blocking
with an HLA-A*0201 blocking antibody. Furthermore, HLA-
A*0201
þ PBMC or OKT3 activated, HLA-A*0201
þ T cells where
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Figure 2 Selection and antigen-specificity of allo-restricted T cells. (A) The CD8
þ Peptide-HLA-A*0201-multimer
þ T cells were sorted by flow
cytometry directed cell sorting. An example for CHM1
319-peptide-specific T cells is given: 1560 cells of 1.5 10
7 input cells were collected in the indicated
gate (arrow). In vitro primed T cells were pooled and stained with a specific peptide CHM1
319/HLA-A*0201-multimer-PE and counterstained with an
anti-human CD8-FITC mAb for cell sorting. Cell sorting was executed on a FACS Aria. (B) Sorted T cells were expanded using limiting dilution and screened
for antigen specificity in IFNg ELISpot: T2 cells pulsed with CHM1
319 (VIMPCSWWV), EZH2
666 (YMCSFLFNL) or as a control FLU (GILGFVFTL) peptide;
T-cell lines screened for CHM1 specificity; line 6, 12 and 17 were further expanded (left). T-cell lines screened for EZH2 specificity; lines 11, 15 and2 4
passed this screen (right). (C) Cos-7 cells were transiently transfected by lipofection with human HLA-A*0201 cDNA and expression constructs with the
gene of interest or GFP cDNA as an irrelevant control (left). HLA-A*0201-specific recognition of ET-cell lines (right). A673 cells are HLA-A*0201
þ
expressing the antigen whereas SBSR-AKS is an ET-cell line expressing the target antigen, but is negative for HLA-A*0201. IFN-g release was measured in
triplicate. Error bars represent s.d. P-values o0.05 indicate significant difference (two-tailed t-tests were used). (D) Flow cytometric determination of peptide
specificity of T-cell lines CHM1-6 (top panel) and EZH2-15 (bottom panel) with specific peptide-multimers, irrelevant peptide-multimers served asac o n t r o l .
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Figure 4 Low granzyme B responses against HLA class I blocked A673, SBSR-AKS and HLA-A*0201
þ PBMC compared with unblocked A673. HLA class
I blocking before granzyme B ELISpots caused reversion of specific recognition by CHM1
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sonly minimally detected by these allo-restricted T cells, supporting
HLA-A*0201-restricted antigen-specific cytotoxicity of our
selected T-cell lines (all Po0.05, two-tailed t-test; Figure 4).
General feasibility of this approach was further demonstrated by
our ability to identify and sufficiently expand several of such T-cell
lines derived of five independent donors tested (Table 1).
ET-specific T cells delay tumour growth in Rag2
 / cC
 / 
mice after adoptive transfer
To analyse whether such allo-restricted cytotoxic T cells can
inhibit tumour growth in vivo, we challenged Rag2
 / gC
 /  mice
s.c. intra-inguinally with EWS-FLI1
þ HLA-A*0201
þ A673 ET
cells, followed by i.v. injection of EZH2 (n¼7) or CHM1 (n¼6)
specific T cells 3 days later (see Materials and Methods). Control
mice (n¼8) did not receive T-cell treatment. Median tumour
weights of mice receiving T cells were significantly lower compared
with control mice (P¼0.015 for EZH2- and 0.039 for CHM1 study
group, respectively, compared with controls, Welch two sample
t-test; Figure 5). None of the treated mice showed any signs of
GvHD upon analysis.
DISCUSSION
Ewing tumour are highly malignant tumours of neuroectodermal
or endothelial origin (Schmidt et al, 1985; Staege et al, 2004) and
are molecularly defined by ews/ets translocations. In all, 85% of ET
are characterized by a specific EWS-FLI1 translocation fusing the
gene coding for the ribosomal binding protein EWS to the gene
coding for the transcription factor FLI1. The resulting chimeric
transcription factor has been implicated in tumour genesis and is
tumour-specific (Kovar, 1998; de Alava and Gerald, 2000).
However, despite an MHC class II restricted peptide derived from
the fusion region of EWS-FLI1 that is able to initiate a CD4
þ T-cell
response (Meyer-Wentrup et al, 2005), no immunogenic
ET-specific MHC class I binding peptide derived from this fusion
region has been identified yet. To further determine possible
ET-specific immunogenic peptides, we utilised high-density DNA
microarrays for the identification of ET-specific gene expression
profiles in comparison with 133 normal tissues of diverse origin
(normal body atlas, NBA) and identified 37 genes that were highly
upregulated or specifically expressed in ET (Staege et al, 2004).
Of these, CHM1 and EZH2 revealed specific or at least strong
overexpression in ET.
Chondromodulin-I is a glycoprotein that is normally expressed
mainly in immature cartilage, stimulating proteoglycan and DNA
synthesis, proliferation and differentiation of chondrocytes. It
inhibits angiogenesis in vitro and in vivo (Hiraki et al, 1997, 1999).
The overexpression of such a molecule in a malignant tumour is
surprising, but may be associated with the reduced microvessel
density in ET and the observation that an increased aggressiveness
of hypoxic tumour cells may correlate with increased metastasis
and inferior prognosis (Dunst et al, 2001). Chondromodulin-I was
previously not known to be tumour-associated.
Enhancer of Zeste, Drosophila Homolog 2 is part of the
polycomb repressor complex 2 (PRC2) and within this complex
it silences target genes by methylating lysine 27 on histone
3 (H3K27). Enhancer of Zeste, Drosophila Homolog 2 is already
active at gastrulation (Sparmann and van Lohuizen, 2006). We
found EWS-FLI1 to be bound to the EZH2 promoter in vivo,
inducing EZH2 expression in ET and mesenchymal stem cells.
Downregulation of EZH2 by RNA interference suppressed
ET tumour development and metastasis in immunodeficient
Rag2
 / gC
 /  mice. Enhancer of Zeste, Drosophila Homolog
2 maintained an undifferentiated stemness phenotype in ET
(Richter et al, 2009), implicating that EZH2 might have a central
role in ET pathology (Burdach et al, 2009). Enhancer of Zeste,
Drosophila Homolog 2 upregulation is known to be associated
with poor prognosis in prostate cancer (Varambally et al, 2002). As
polycomb group proteins are known to be vitally involved in
transcriptional control and carcinogenesis in several human
tumours (Simon and Lange, 2008), EZH2 may be less susceptible
to the development of immune escape variants. Peptide EZH2
666
Table 1 CHM1 and EZH2-specific T-cell line data from five different donors
Donor
no. Peptide
Sorted
cells
Tested
lines
Best specified
T-cell lines
T2+rel/irr peptide
mean of IFNc
A673/SBSR-AKS mean
of IFNc or GB spots
Expansion factor
after 14 days
1 CHM1-319 1560 96 2
a 19.6 and 145 30.7 (IFNg) 80–100
2 EZH2-666 5418 96 4
a 1.8, 57.8, 490 and 15 10.1 (IFNg) 100–140
3 CHM1-319 590 48 1 5 4.9 (GB) 17
4 CHM1-319 706 9 2 1.6 and 2.3 3.6 and 6.8 (IFNg)2 2 – 2 4
5 CHM1-319 2160 48 1 61.5 11.1 (IFNg)5 0 – 8 0
Abbreviations: IFNg¼interferon-g; irr¼irrelevant; GB¼granzyme B; rel¼relevant.
aOnly one cell line was further tested for A673 and SBSR-AKS discrimination. CD8
+ T Cells
(6 10
6 to 1 10
8) from five different HLA-A*0201
  healthy donors were stained and screened for the presence of CHM1
319 or EZH2
666 peptide-specific CD8
+ T cells after
priming with peptide-loaded HLA-A*0201
+ dendritic cells. Expanded T-cell lines were tested for specificity in IFNg (and granzyme B for donor no. 3) ELISpot assays using T2 cells
pulsed with either relevant or irrelevant peptides and A673 and SBSR-AKS Ewing tumour cell lines as targets with an ratio of 1000 T cells/20000 target cells (or 200000 T cells/
20000 target cells in granzyme B assays). Numbers, specificity data and expansion rates are given.
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Figure 5 ET-specific T cells delay tumour growth in Rag2
 / gC
 /  mice
after adoptive transfer. Rag2
 / gC
 /  mice were challenged s.c. intra-
inguinally with 2 10
6 EWS-FLI1
þ HLA-A*0201
þ A673 ET cells and
received 2 10
6 CHM1
319 or EZH2
666-specific T cells by i.v. injection 3
days later. Mice were killed and analysed on day 17. Individual mice are
represented by symbols. Median tumour weights are indicated by black
bars. A P-value o0.05 indicates a significant difference between tumour
weights of mice treated with EZH2-15 or CHM1-6 compared with
controls (Welch two sample t-test).
Specific Ewing tumour lysis by allo-restricted T cells
U Thiel et al
953
British Journal of Cancer (2011) 104(6), 948–956 & 2011 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
swas already validated as a target for cancer immunotherapy (Steele
et al, 2006).
Mixed results have been observed with autologous SCT for
patients with high risk or recurrent ET. Whereas some studies
reported improved disease free survival over historical controls
(Burdach et al, 1991, 2003; Paulussen et al, 1998; Burdach, 2004),
others observed no long-term benefit compared with conventional
therapies (Cotterill et al, 2000; Meyers et al, 2001). These findings
emphasise the need for alternative approaches. In ET patients with
vast bone affection and poor prognosis, allogeneic SCT is a therapy
option (Burdach et al, 2000; Koscielniak et al, 2005; Lucas et al,
2008). However, the desired GvT effect is intrinsically tied to an
often-pronounced GvHD, mediated by allo-reactive T cells.
To specifically direct such T cells against the tumour, it is
necessary to identify the allo-restricted tumour-specific T cells
within an allogeneic T-cell population (Dutoit et al, 2002; Mutis
et al, 2002; Amrolia et al, 2003; Whitelegg et al, 2005; Schuster
et al, 2007).
A recent retrospective study based on data drawn from the
EBMT-, PRST-, APBMT-, and MetaEICESS-registries revealed that
there is no improvement of survival of ET patients receiving
reduced intensity conditioning compared with high-dose
conditioning before allogeneic stem cell transplantation with
HLA-matched grafts, implicating absence of a clinically relevant
graft vs ET effect (Thiel et al, 2011). Reduced intensity condition-
ing regimen followed by haploidentical stem cell transplantation is
subject to various ongoing prospective trials and may increasingly
replace HLA-matched approaches. Thus, HLA-A*0201
þ ET
patients may profit from a treatment based on adoptive transfer
from ET-specific T cells of an HLA-A*0201
  donor after
haploidentical stem cell transplantation.
We isolated allo-restricted T cells by MHC multimer-staining
and cell sorting. Using this technique, we have succeeded in
establishing T-cell lines directed against several HLA-A*0201-
restricted peptides derived from ET-specific antigens. Reliable
in silico prediction algorithms are helpful tools to identify a CTL
epitope (Larsen et al, 2005). Still, in silico high scoring epitope
candidates have to be confirmed for binding to HLA-A*0201.
We not only verified the already published EZH2
666 peptide as a
binding peptide on T2 cells (Steele et al, 2006), but identified
CHM
319 as a new good binding peptide (Supplementary Figure 1).
As CHM1
319 had been a previously undescribed peptide, it could
have been possible that it represented an artificial epitope.
Therefore, the simian cell line Cos-7 was co-transfected with
vectors containing the human HLA-A*0201 gene and the gene
of interest. Again, not only the EZH2
666 peptide-specific T cells
recognised such double-transfected Cos-7 cells, but also the
CHM
319 peptide-specific T cells specifically released IFN g when
contacting Cos-7 co-transfected cells, indicating processivity of
these peptide epitopes. Even though EZH2 is expressed at a low
level on a variety of tissues compared with CHM1, it may
nevertheless constitute an appropriate target for T-cell therapy
after successful engraftment, because of its particularly high
expression in ET. The risk of GvHD caused by EZH2
666-specific T
cells is likely to be lower than the risk associated with infusion of
blunt donor lymphocytes. Nevertheless, CHM1 represents a more
appropriate target and further ET-specific targets remain to be
identified and tested.
The T cells isolated here not only specifically recognised peptide-
pulsed or antigen-transfected cells in the context of HLA-A*0201, but
also released granzyme B when recognising HLA-A*0201
þ ET
expressing the antigen, while other HLA-A*0201
þ tumour lines and
HLA-A*0201 negative ET were not affected. Furthermore, efficacy of
allo-restricted EZH2
666 and/or CHM1
319 specific T cells were
confirmed in a xenograft mouse model, where ET growth was
significantly delayed after adoptive transfer of such T cells compared
with controls and GvHD was absent.
Although we could demonstrate the general feasibility of our
approach, with which we were able to generate allo-restricted
ET-specific T cells in sufficient numbers of every donor tested,
long-term persistence of our T cells in vivo has not been analyzed,
but may be further investigated in a humanised mouse model
(Traggiai et al, 2004). Future approaches generating ET-specific T
cells against EZH2
666 and/or CHM1
319 with a central memory (CM)
phenotype (Berger et al, 2008) in addition may yield improved
anti-tumour efficacy. Furthermore, TCR identification, cloning
and transfection into donor CM CD8
þ T cells before adoptive
transfer may constitute an appropriate tool to simplify the
generation procedure to obtain ET-specific T cells.
However, the generation of highly specific and efficacious
allo-restricted T cells here already yet opens the avenue for new
therapeutic strategies in allogeneic stem cell and effector-cell
transplantation in the treatment of ET patients.
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